News | August 10, 2023
Suven Life Sciences posts Q1 FY24 consolidated loss at Rs. 24.09 Cr
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Subscribe To Our Newsletter & Stay Updated
